Literature DB >> 6375338

Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Collaborative Group for Amiodarone Evaluation.

.   

Abstract

The clinical efficacy of a low-dosage schedule of amiodarone was tested in 58 patients with severe ventricular arrhythmias refractory to other drug treatments. The initially chosen regimen of 400 mg was effective at the end of the first controlled trial period (after 4 weeks) in 73% of the patients. The responsiveness was maintained with the smaller dosage of 200 mg in 68% of this group. The response was reestablished also in the patients who became nonresponders during the low-dose regimen when they returned to the initial (400-mg) dosage. No relation was found between clinical response and blood levels of amiodarone and of its deethylated metabolite. Adverse effects more often associated with amiodarone therapy were rare. However, careful monitoring of thyroid function allowed the detection in 10% of the patients of biochemically and functionally documented, but clinically silent, cases of hypo- or hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375338     DOI: 10.1016/0002-9149(84)90580-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Amiodarone therapeutic plasma concentration monitoring. Is it practical?

Authors:  T Maling
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

2.  Effect on growth of children with cardiac dysrhythmias treated with amiodarone.

Authors:  J Ardura; F Hermoso; J Bermejo
Journal:  Pediatr Cardiol       Date:  1988       Impact factor: 1.655

3.  Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers.

Authors:  E Riva; L Aarons; R Latini; P Neyroz; R Urso
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Amiodarone-induced pulmonary toxicity--a fatal case report and literature review.

Authors:  Felix T Range; Ekkehard Hilker; Günter Breithardt; Boris Buerke; Pia Lebiedz
Journal:  Cardiovasc Drugs Ther       Date:  2013-06       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.